Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation
Primary Purpose
Hip Fracture
Status
Suspended
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Intracapsular Femoral Fracture Fixation
WaisFix100i for Intracapsular Femoral Fracture Fixation
Sponsored by
About this trial
This is an interventional treatment trial for Hip Fracture focused on measuring Hip Prosthesis Implantation
Eligibility Criteria
Inclusion Criteria:
- Male/Female with Intracapsular femoral fracture type Garden I-II and several III.
- Age 50 to 75.
- Subject able to comprehend and give informed consent for participation in this study.
Exclusion Criteria:
- Known active infectious disease.
- Terminal diseases
- Patients in high risk and/or acute cardio-vascular disease.
- Known cognitive disorder, psychiatric and/or neurological disease
- Physician objection.
- Age under 50 or above 75.
- Concurrent participation in any other clinical study
- Patients cannot understand or not willing to sign the informed consent.
Sites / Locations
- carmel Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
A
Arm Description
Outcomes
Primary Outcome Measures
The safety endpoint is measure by paucity incidence of treatment related major complications.
Secondary Outcome Measures
Efficacy endpoint is measure by the following: 1. A subject is scored a success if he had no revision surgery, hemi- arthroplasty or total hip replacement surgery by 12 months; 2. Time to functional recovery
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00521716
Brief Title
Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation
Official Title
A Single Arm, Uni-Center, Prospective Clinical Investigation to Evaluate Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation
Study Type
Interventional
2. Study Status
Record Verification Date
February 2008
Overall Recruitment Status
Suspended
Study Start Date
September 2007 (undefined)
Primary Completion Date
March 2008 (Anticipated)
Study Completion Date
December 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
OrthoMediTec
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine the safety and efficacy of using WaisFix100i device for Intracapsular Femoral Fracture Fixation.
Detailed Description
Fractures of the neck of the femur represent an estimated cost to society that exceeds ten billion dollars annually in the USA only.
Fractures have been treated with immobilization, traction, amputation, and internal fixation throughout history. Immobilization by casting, bracing, or splinting a joint above and below the fracture was used for most long bone fractures.
Several studies have suggested that reduction and fixation of an Intracapsular fracture of the hip with multiple pins or screws is associated with a lower rate of morbidity and mortality than treatment with prosthetic replacement. With improved methods of fixation and a tendency toward earlier weight-bearing, internal fixation is believed to be a better mode of treatment for younger, more active patients.
On the other hand, the internal fixation procedure may result with number of possibilities for serious complications and biomechanical disadvantages, leading to the device failure. This led to a growing tendency to prefer total or partial hip replacement as the common treatment for intracapsular fracture, although the internal fixation is the favorable procedure in the professional literature.
OrthoMediTec has developed the WaisFix100i device, a new concept for Intracapsular Femoral Fracture Fixation and bone grafting using minimally invasive procedures. The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
The Internal Triangular Cage is inserted into the femoral neck as a strong, solid beam structure to guide and hold the screws in place. The cage supplies the structure to hold the bone graft and screws at the fracture site.
The objectives of this single arm, multi-center, prospective study, are to evaluate the safety and efficacy of using the WaisFix100i device in intracapsular femoral fracture fixation surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Fracture
Keywords
Hip Prosthesis Implantation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Intracapsular Femoral Fracture Fixation
Other Intervention Name(s)
WaisFix100i
Intervention Description
The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
Intervention Type
Device
Intervention Name(s)
WaisFix100i for Intracapsular Femoral Fracture Fixation
Intervention Description
The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
Primary Outcome Measure Information:
Title
The safety endpoint is measure by paucity incidence of treatment related major complications.
Time Frame
Study duration
Secondary Outcome Measure Information:
Title
Efficacy endpoint is measure by the following: 1. A subject is scored a success if he had no revision surgery, hemi- arthroplasty or total hip replacement surgery by 12 months; 2. Time to functional recovery
Time Frame
Study duration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male/Female with Intracapsular femoral fracture type Garden I-II and several III.
Age 50 to 75.
Subject able to comprehend and give informed consent for participation in this study.
Exclusion Criteria:
Known active infectious disease.
Terminal diseases
Patients in high risk and/or acute cardio-vascular disease.
Known cognitive disorder, psychiatric and/or neurological disease
Physician objection.
Age under 50 or above 75.
Concurrent participation in any other clinical study
Patients cannot understand or not willing to sign the informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc Waisman, Dr.
Organizational Affiliation
Carmel medical Center, Haifa Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
carmel Medical Center
City
Haifa
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation
We'll reach out to this number within 24 hrs